Johnson & Johnson (JNJ) Shares Bought by Madrona Financial Services LLC
Madrona Financial Services LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% during the first quarter, according to its most recent filing with the SEC. The fund owned 2,617 shares of the company’s stock after buying an additional 43 shares during the period. Johnson & Johnson accounts for 0.3% of Madrona Financial Services LLC’s investment portfolio, making the stock its 29th largest position. Madrona Financial Services LLC’s holdings in Johnson & Johnson were worth $326,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. boosted its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $117,000. Taylor Wealth Management Partners boosted its position in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the period. Foundation Resource Management Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $204,000. Finally, Arbor Investment Advisors LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $215,000. Hedge funds and other institutional investors own 65.98% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.36% on Wednesday, hitting $131.74. The stock had a trading volume of 927,450 shares. The company has a market cap of $353.59 billion, a price-to-earnings ratio of 22.29 and a beta of 0.78. The firm has a 50 day moving average price of $132.91 and a 200-day moving average price of $127.75. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 21.58% and a net margin of 20.31%. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter last year, the business posted $1.74 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Madrona Financial Services LLC” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-madrona-financial-services-llc/1532106.html.
Several brokerages recently issued reports on JNJ. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 price objective on the stock. in a research note on Monday, May 8th. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Wells Fargo & Co restated a “market perform” rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, UBS AG restated a “buy” rating and set a $136.00 price objective on shares of Johnson & Johnson in a research note on Monday, May 15th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $133.91.
In related news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.